Blue Bear Ventures

Unnatural Products Inc. is a biotechnology company based in Santa Cruz, California, specializing in drug discovery through the innovative use of macrocyclic peptides. Founded in 2016, the company employs artificial intelligence and computational biology techniques to engineer these peptides, allowing them to target previously undruggable protein interactions. By leveraging machine learning for parallel chemical synthesis, Unnatural Products aims to optimize macrocyclic compounds efficiently, thereby accelerating the drug discovery process. This technology addresses a significant gap in therapeutic strategies, offering potential treatments for a wide range of diseases linked to difficult-to-target drug candidates.

ImpriMed, Inc. is a company that specializes in drug testing services, focusing on the responses of live cancer cells from pets, particularly those with lymphoma. Based in Palo Alto, California, with a branch office in Seoul, South Korea, ImpriMed uses individualized drug response prediction technology to assist veterinary oncologists in selecting appropriate anticancer treatments. By collecting genetic and cellular information from pet cancer cells, the company creates a patient-derived database that not only aids in veterinary oncology but also holds potential for applications in human cancer care. This data-driven approach enables veterinarians to make informed decisions on final treatment regimens, ultimately enhancing precision medicine in both animal and human oncology. ImpriMed was incorporated in 2017.

engageLively provides a cloud-based analytics service with a built-in visual application studio that helps firms organize, analyze, and visualize their data. They also provide arbitrary extensibility in hardware, software, memory, and storage.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, DNALite utilizes innovative oral lipid nanoparticle technology to deliver mRNA and pDNA directly to intestinal stem cells. This approach targets the underlying causes of diseases such as Familial Adenomatous Polyposis, a hereditary form of colorectal cancer that often necessitates invasive surgeries in adolescents. By enabling the intestinal tract to secrete therapeutic proteins into the bloodstream, DNALite aims to transform conventional protein biologics into oral medications, potentially improving patient outcomes and accessibility to treatment.